Strong equity market conditions and sustained investor appetite for growth-oriented sectors, particularly AI and technology, underpin elevated market-implied odds for several high-profile IPOs before year-end 2026. As of late October, the pipeline shows continued momentum, with Anthropic filing its S-1 on October 26 targeting a substantial raise amid $4.6 billion in reported revenue growth, alongside multiple U.S. deals pricing or scheduled through October 30 including OPay, Aspen Neuroscience, and Bambusa Therapeutics. Year-to-date activity exceeds 135 priced IPOs, supported by favorable Nasdaq performance and Treasury yields that have eased financing conditions relative to prior periods. Upcoming catalysts such as earnings visibility, regulatory clearances, and potential additional filings before December 31 could further influence trader consensus on individual resolutions, though execution risks around valuation and market volatility remain relevant factors priced into current levels.
Este mercado se resolverá a favor de "Sí" si la empresa cotizada completa una oferta pública inicial (OPI) a más tardar el 31 de diciembre de 2026, 23:59 ET, según lo confirmen anuncios oficiales de la empresa o fuentes de noticias fiables. La OPI se refiere a la primera venta de acciones de la empresa indicada al público en cualquier bolsa de valores reconocida. Si la empresa cotizada se fusiona con otra entidad, es adquirida o deja de existir antes de que se resuelva el mercado, el mercado también se resolverá a favor de "No". Este mercado se resolverá anticipadamente si la empresa cotizada completa una OPI a más tardar el 31 de diciembre de 2026, 23:59 ET. La resolución de este mercado se basará en el consenso de fuentes informativas fiables.
Traducción automática. En caso de disputa, prevalece el original.